Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.
Products, services, technology
Vamorolone, a dissociative steroid, is the lead pipeline candidate in development for the treatment for Duchenne muscular dystrophy. NDA, MAA are under review by FDA/EMA and submitted to UK MHRA. Lonodelestat has Ph2a studies in cystic fibrosis (CF) and an acute pulmonary indication in preparation.
Vamorolone and lonodelestat represent platform type pipeline molecules, each with potential for out-licensing or development in a range of additional indications beyond their prime indications Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF), respectively, in collaboration with partners.